ABOUT US
We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.
QUALITY
As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.
WHO WE ARE
We deliver pharma products from Switzerland and from all over the world.
Our team in ELIXI International has a solid experience in the distribution of medical products.
History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.
NEWS
FDA approves Fulphila (pegfilgrastim-jmdb) first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment
The U.S. Food and Drug Administration has approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the…
New indication approval for Keytruda (pembrolizumab)
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent…
FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for…
EU positive opininion on Rxulti (brexpiprazole) for the treatment of Schizophrenia
On 31 May 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…
FDA Approves OLUMIANT (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
Eli Lilly and Company and Incyte Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of…
New medicine for hereditary rare disease: Tegsedi (Inotersen) addresses unmet medical need for treatment of hereditary transthyretin amyloidosis
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU)…
Xeljanz (tofacitinib), first oral medication approved for moderately to severely active ulcerative colitis
The U.S. Food and Drug Administration has expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely…
UCB Announces the Approval of CIMZIA (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis
The U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA (certolizumab pegol) to include a new indication…
The European Commission has approved Novartis unit Sandoz’ Zessly ( Infliximab) a biosimilar version of Johnson & Johnson and Merck’s Remicade.
Sandoz, a Novartis division and the global leader in biosimilars, today announced that the European Commission (EC) has approved Zessly (infliximab)…
Amgen receives FDA approval to expand use of Prolia (denosumab) to patients with Glucocorticoid-Induced Osteoporosis
US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men…
CONTACT US
ELIXI International SA
Piazza Boffalora 4
6830 Chiasso / Switzerland
Tel: +41 91 682 20 40